Please provide your email address to receive an email when new articles are posted on . Cal/BDP is a combination formula, comprised of calcipotriol and betamethasone dipropionate, that treats ...
The Food and Drug Administration (FDA) announced that it has accepted the supplemental New Drug Application (sNDA) for roflumilast foam 0.3% in adults and adolescents with scalp and body psoriasis ...
The foam formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast has been approved by the US Food and Drug Administration (FDA) for treating plaque psoriasis of the scalp and body in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results